source
- Roche signs $400 million upfront deal with China's Hansoh, potential $15 billion partnershipRoche announced a major collaboration with Chinese biotech Hansoh, committing $400 million upfront. The agreement gives Roche access to Hansoh's drug discovery platform and aims to co-develop cand…
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…